Phagos develops customizable bacteriophage therapies that target specific antibiotic-resistant bacteria, providing a rapid and effective alternative to traditional antibiotics. By harnessing the natural adaptability of bacteriophages, the company can create tailored solutions within two months to combat the growing threat of antimicrobial resistance.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DEF+1Founders
Product
Problem
Antimicrobial resistance is a growing global health threat, with bacteria becoming increasingly resistant to traditional antibiotics, leading to ineffective treatments for infectious diseases. This resistance results in significant economic losses and a projected increase in mortality rates, potentially surpassing cancer-related deaths by 2050.
Solution
Phagos develops customizable bacteriophage therapies to combat specific antibiotic-resistant bacteria. By harnessing the natural evolutionary capabilities of bacteriophages, Phagos creates tailored solutions to eliminate targeted bacteria with high efficiency and speed. Their process allows for the development of new treatments from scratch within two months, providing a rapid alternative to conventional antibiotics. These customizable drugs address the challenges posed by antimicrobial resistance by offering targeted and adaptable solutions.
Target Audience
The primary target audience includes healthcare providers, pharmaceutical companies, and research institutions seeking innovative solutions to combat antibiotic-resistant infections.
Features
- Customizable bacteriophage therapies targeting specific antibiotic-resistant bacteria
- Rapid development of new treatments within two months
- Harnessing the natural evolutionary potential of bacteriophages for adaptability
- Highly efficient elimination of targeted bacteria